Article Text

PDF

Salbutamol and ipratropium in COPD
  1. Magnus Harrison,
  2. Ross Murphy
  1. Department of Emergency Medicine, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK

    Statistics from Altmetric.com

    Report by Magnus Harrison, Clinical Research Fellow Search checked by Ross Murphy, Senior Clinical Fellow

    Clinical scenario

    A 59 year old man presents with an exacerbation of COPD. You wonder whether it is better to nebulise salbutamol or ipratropium bromide alone, or a combination of the two.

    Three part question

    In [patients presenting with an acute exacerbation of COPD] is nebulisation of [a beta 2 agonist alone, ipratropium bromide alone or a combination of the two] more effective at [controlling and improving symptoms].

    Search strategy

    Medline 1966–11/00 using the OVID interface. {{[(exp chronic disease OR exp hospitals, chronic disease OR chronic.mp) AND (exp lung disease, obstructive OR obstructive.mp)] OR exp emphysema OR exp pulmonary emphysema OR emphysema.mp OR exp bronchitis OR bronchitis.mp OR exp COPD.mp OR COAD.mp OR airway obstruction.mp)} AND (acute.mp or exacerbation.mp)} AND (exp ipratropium OR ipratropium bromide.mp OR atrovent.mp OR antimuscarinic.mp OR exp. muscarinic antagonist OR exp brochodilators agents OR bronchodilators.mp OR exp albuterol OR salbutamol.mp OR beta 2 agonist.mp OR exp terbutaline) AND (exp nebulisers OR vaporises.mp OR exp respiratory therapy OR nebulisers.mp) NOT (exp child OR children.mp OR exp paediatrics OR paediatric.mp) LIMIT to human AND english.

    Search outcome

    Altogether 162 papers found of which 157 were irrelevant or of insufficient quality. The remaining five papers are shown in table 3.

    Table 3

    Comments

    There are five randomised trials that address the three part question. All of the studies are of reasonable quality.

    Clinical bottom line

    Initial treatment can be either salbutamol or ipratropium nebulisers alone. There is no evidence to suggest that using both has additional benefit.

    Report by Magnus Harrison, Clinical Research Fellow Search checked by Ross Murphy, Senior Clinical Fellow

    References

    View Abstract

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.